Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BDX Stock Forecast 2026-2027
$151.16
Current Price
$41.65B
Market Cap
Buy 6
Hold 9
Sell 0
Wall St Analyst Ratings
Distance to BDX Price Targets
+48.8%
To High Target of $225.00
+15.8%
To Median Target of $175.00
-0.8%
To Low Target of $150.00
BDX Price Momentum
+2.7%
1 Week Change
+4.4%
1 Month Change
+10.9%
1 Year Change
-0.9%
Year-to-Date Change
-19.3%
From 52W High of $187.35
+18.5%
From 52W Low of $127.59
📊 TOP ANALYST CALLS
Did BDX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if BD is one of their latest high-conviction picks.
Latest BDX Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, BDX has a neutral consensus with a median price target of $175.00 (ranging from $150.00 to $225.00). The overall analyst rating is Buy (7.6/10). Currently trading at $151.16, the median forecast implies a 15.8% upside. This outlook is supported by 6 Buy, 9 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BDX Analyst Ratings
6
Buy
9
Hold
0
Sell
BDX Price Target Range
Low
$150.00
Average
$175.00
High
$225.00
Current: $151.16
Latest BDX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BDX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 11, 2026 | Barclays | Matt Miksic | Overweight | Maintains | $204.00 |
| May 8, 2026 | Wells Fargo | Lawrence Biegelsen | Equal-Weight | Maintains | $161.00 |
| May 4, 2026 | TD Cowen | Joshua Jennings | Hold | Maintains | $163.00 |
| Apr 17, 2026 | Piper Sandler | Neutral | Maintains | $N/A | |
| Apr 10, 2026 | Goldman Sachs | David Roman | Neutral | Reinstates | $167.00 |
| Mar 26, 2026 | Piper Sandler | Neutral | Maintains | $N/A | |
| Mar 23, 2026 | Argus Research | Buy | Maintains | $N/A | |
| Feb 11, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Feb 11, 2026 | Barclays | Matt Miksic | Overweight | Reinstates | $202.00 |
| Feb 10, 2026 | JP Morgan | Neutral | Maintains | $N/A | |
| Feb 10, 2026 | Jefferies | Buy | Maintains | $N/A | |
| Feb 10, 2026 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Feb 10, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Feb 10, 2026 | Piper Sandler | Neutral | Reiterates | $N/A | |
| Feb 10, 2026 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Jan 28, 2026 | Piper Sandler | Neutral | Maintains | $N/A | |
| Jan 7, 2026 | Stifel | Buy | Maintains | $N/A | |
| Jan 5, 2026 | B of A Securities | Neutral | Maintains | $N/A | |
| Dec 17, 2025 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Dec 2, 2025 | Morgan Stanley | Overweight | Maintains | $N/A |
Becton, Dickinson and Company (BDX) Competitors
The following stocks are similar to BD based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Becton, Dickinson and Company (BDX) Financial Data
Becton, Dickinson and Company has a market capitalization of $41.65B with a P/E ratio of 26.1x. The company generates $22.23B in trailing twelve-month revenue with a 5.1% profit margin.
Revenue growth is +5.2% quarter-over-quarter, while maintaining an operating margin of +14.7% and return on equity of +6.7%.
Valuation Metrics
Market Cap
$41.65B
Enterprise Value
$57.67B
P/E Ratio
26.1x
PEG Ratio
-0.1x
Price/Sales
1.9x
Growth & Margins
Revenue Growth (YoY)
+5.2%
Gross Margin
+45.7%
Operating Margin
+14.7%
Net Margin
+5.1%
EPS Growth
-10.6%
Financial Health
Cash/Price Ratio
+2.0%
Current Ratio
0.9x
Debt/Equity
71.6x
ROE
+6.7%
ROA
+4.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Becton, Dickinson and Company (BDX) Business Model
About Becton, Dickinson and Company
What They Do
Global medical technology company providing healthcare solutions.
Business Model
The company generates revenue through the development and sale of medical supplies, devices, and diagnostic products across various healthcare sectors. Its operations are segmented into medical delivery solutions, advanced interventional products, and specialized instruments and reagents, catering to hospitals, laboratories, and biopharmaceutical customers.
Additional Information
Founded in 1897 and headquartered in Franklin Lakes, New Jersey, Becton, Dickinson and Company is a recognized leader in the medical instruments and supplies market, playing a crucial role in infection prevention and clinical workflows worldwide.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
60,000
CEO
Mr. Thomas E. Polen Jr.
Country
United States
IPO Year
1983
Website
www.bd.comBecton, Dickinson and Company (BDX) Latest News & Analysis
Latest News
BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
16 days ago
Quick Summary
A new laser system has been developed to improve efficiency and workflow for urology teams in stone management and soft tissue procedures, based in Franklin Lakes, N.J.
Why It Matters
The new laser system could improve operational efficiency in urology, potentially increasing demand for related medical services and products, impacting revenue for healthcare companies involved.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
BDX has introduced the Elyra Thulium Fiber Laser system, aimed at improving kidney stone treatment and enhancing workflow for urology teams.
Why It Matters
BDX's launch of the Elyra Thulium Fiber Laser system enhances urology care efficiency, potentially increasing market share and revenue, which can positively impact stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
BD (Becton, Dickinson and Company) has appointed Peter Menziuso as executive vice president and president of BD Interventional, effective June 1, 2026.
Why It Matters
Leadership changes can impact company strategy and performance. Investors may assess Menziuso's track record and vision for BD Interventional, influencing stock sentiment and market confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Investors face uncertainty as a new presidential administration takes office on Jan. 20, 2025, potentially impacting stock market dynamics and interest rates through policy changes.
Why It Matters
Upcoming presidential changes could lead to significant shifts in economic policies, impacting market stability, interest rates, and trade dynamics, influencing investor sentiment and strategies.
Source: Investopedia
Market Sentiment:
Neutral
Quick Summary
BD CEO Tom Polen predicts that AI and robotics will significantly transform healthcare in the next decade, making current systems appear outdated.
Why It Matters
Polen's statement highlights potential growth in the medical tech sector, signaling opportunities for investment in AI and robotics that could disrupt traditional healthcare models.
Source: Bloomberg Technology
Market Sentiment:
Positive
Becton, Dickinson and Company (BDX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
24 days ago
Quick Summary
Becton, Dickinson and Company (BDX) presented at the Bank of America Global Healthcare Conference, discussing future strategies and insights relevant to investors.
Why It Matters
BDX's presentation at a major healthcare conference signals its strategic direction and growth potential, influencing investor sentiment and stock performance in the healthcare sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About BDX Stock
What is Becton, Dickinson and Company's (BDX) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, Becton, Dickinson and Company (BDX) has a median price target of $175.00. The highest price target is $225.00 and the lowest is $150.00.
Is BDX stock a good investment in 2026?
According to current analyst ratings, BDX has 6 Buy ratings, 9 Hold ratings, and 0 Sell ratings. The stock is currently trading at $151.16. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BDX stock?
Wall Street analysts predict BDX stock could reach $175.00 in the next 12 months. This represents a 15.8% increase from the current price of $151.16. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Becton, Dickinson and Company's business model?
The company generates revenue through the development and sale of medical supplies, devices, and diagnostic products across various healthcare sectors. Its operations are segmented into medical delivery solutions, advanced interventional products, and specialized instruments and reagents, catering to hospitals, laboratories, and biopharmaceutical customers.
What is the highest forecasted price for BDX Becton, Dickinson and Company?
The highest price target for BDX is $225.00 from at , which represents a 48.8% increase from the current price of $151.16.
What is the lowest forecasted price for BDX Becton, Dickinson and Company?
The lowest price target for BDX is $150.00 from at , which represents a -0.8% decrease from the current price of $151.16.
What is the overall BDX consensus from analysts for Becton, Dickinson and Company?
The overall analyst consensus for BDX is neutral. Out of 7 Wall Street analysts, 6 rate it as Buy, 9 as Hold, and 0 as Sell, with a median price target of $175.00.
How accurate are BDX stock price projections?
Stock price projections, including those for Becton, Dickinson and Company, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 6, 2026 2:13 AM UTC